AlphAIalphai — Financial news for AI agents
finance.yahoo.comMAY 275 min read$COLL

Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio

Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 2026 results on May 7, with revenue up 9% YoY to $193.5 million, beating the Street’s $187.4 million estimate. Adjusted EPS rose to $1.76 from $1.49 and topped expectations of $1.63. The company cited strong ADHD franchise growth, including Jornay PM sales up 36% YoY, and expects Jornay PM revenue of $190–$200 million in 2026. Collegium also plans to expand its ADHD portfolio via Azstarys acquisition, expecting it to add over $50 million to H2 2

Original reporting
finance.yahoo.com
Published May 27, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$COLLBullishHigh
01

Why it matters

Q1 outperformance plus explicit 2026 revenue expectations for Jornay PM and expected H2 2026 revenue from Azstarys create a clear catalyst chain for re-rating growth prospects.

02

Market read

A fundamentals catalyst (earnings beat) combined with product-level growth metrics and forward revenue contribution expectations for ADHD drugs.

03

What to watch

The piece doesn’t address competitive intensity, payer restrictions, or execution risks in scaling subscriber base and patient awareness for Jornay PM/Azstarys.

Relevance 9/10Timing: Q1 2026 results (reported May 7) with forward-looking 2026 revenue targets and H2 2026 Azstarys contribution.

Background

The article frames Collegium as gaining attention due to strong ADHD franchise performance and a planned expansion of its ADHD portfolio via Azstarys.

Company-level read

Ticker impact

$COLLBullishHigh confidence
Context

Collegium reported Q1 2026 results that beat Street expectations and highlighted strong ADHD growth in Jornay PM plus Azstarys expansion plans.

Expected impact

Near-term upside bias as investors re-rate the ADHD growth trajectory and H2 2026 revenue contribution from Azstarys.

Evidence & confidence

The article cites Q1 revenue/EPS beats, 36% YoY Jornay PM sales growth, and a specific H2 2026 revenue contribution expectation (> $50M) tied to Azstarys.

Market effects

Sector

Reinforces bullish read-through for ADHD specialty pharma demand, prescriptions, and prescriber expansion dynamics.

Regional

Limited—company-specific catalyst centered on Massachusetts-based Collegium’s product pipeline and commercial execution.

Global

Moderate—ADHD therapeutics demand signals can influence sentiment across specialty pharma, though the article is US-focused.

Counterpoint

What could challenge this read

Azstarys contribution depends on continued prescription/prescriber momentum; any slowdown could pressure the implied 2026 growth path.

Key entities

  • company
    Collegium Pharmaceutical Inc.

    Reported Q1 2026 results that beat expectations; highlighted Jornay PM growth and Azstarys expansion with >$50M H2 2026 revenue expectation.

  • product
    Jornay PM

    ADHD medicine whose sales jumped 36% YoY in Q1, supporting management’s 2026 growth outlook.

  • product
    Azstarys

    ADHD portfolio expansion; expected to contribute more than $50M to H2 2026 revenue per management.

Read at source← All news

Related articles

AUG 13
$COLLMedAI 8/10

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) reported Q2 2026 results on an earnings call. Total net product revenue was $199.9M (+6% YoY). Jornay PM revenue rose to $46.1M (+41%) with 30,000+ prescribers. Azstarys revenue was $12.9M post-May acquisition. 2026 guidance: product revenue $825M-$855M; adjusted EBITDA $445M-$470M; adjusted EPS $1.92. Risks cited include authorized-generic pricing impacts.

fool.com8 min
AUG 13
$COLLMed

Why is Collegium Pharmaceutical stock climbing today?

Collegium Pharmaceutical shares rose about 3% in pre-open trading after the company announced a $50 million Accelerated Share Repurchase with Jefferies LLC. Collegium will pay $50 million upfront and receive about 1.56 million shares initially, under a $150 million buyback program authorized in July 2025. The firm reported Q2 net revenues near $199.9 million and reaffirmed 2026 guidance of $805–$825 million.

investing.com4 min
AUG 13
$COLLMed

Collegium Pharmaceutical stock jumps on $50M share buyback

Collegium Pharmaceutical (NASDAQ:COLL) shares rose about 4% premarket after it announced a $50 million accelerated share repurchase with Jefferies LLC. The ASR is part of a $150 million buyback authorized in July 2025, leaving $100 million after completion. Collegium will pay $50 million and initially receive 1,556,420 shares based on a $25.70 Aug. 12, 2026 close; final settlement expected by Q4 2026.

investing.com2 min
AUG 6
$COLLHighAI 9/10

Why is Collegium Pharmaceutical stock tumbling today?

Collegium Pharmaceutical shares fell about 13% in pre-open trading after it reported Q2 2026 results and cut full-year revenue guidance. Net revenues were $199.9M, up 6.3% but below analysts’ ~$201.2M-$201.4M. Adjusted EPS was $1.92 and adjusted EBITDA $113.8M. The pain portfolio faced generic competition, while JORNAY PM rose 41% to $46.1M and AZSTARYS added $12.9M.

investing.com4 min
AUG 6
$COLLHigh

COLLEGIUM PHARMACEUTICAL, INC (COLL): Results of Operations and Financial Condition

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Y

SEC EDGAR 8-K7 min